LENZ Therapeutics LENZ Income Statement (2020-2026)

NASDAQ LENZ
$4.66 -0.26 (-5.28%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
5.00M12.50M-12.50M1.90M5.49M
Cost of Revenue (Quarter)
1.08M0.28M
Gross Profit (Quarter)
0.82M5.21M
Operating items
Research & Development (Quarter)
8.68M11.21M18.25M17.78M18.30M18.46M10.32M12.64M17.00M19.54M10.54M6.95M6.45M5.87M5.82M9.06M3.79M
Selling, General & Administrative (Quarter)
5.92M7.74M7.71M9.00M7.85M8.29M2.29M2.32M2.86M5.45M5.55M7.41M6.49M9.36M11.11M12.80M27.60M0.50M44.96M39.38M
Restructuring Costs (Quarter)
5.30M0.20M
Other Operating Expenses (Quarter)
-0.07M39.55M1.08M0.28M
Operating Expenses (Quarter)
14.60M18.94M25.96M26.78M26.15M26.75M12.62M14.96M19.86M24.99M16.09M14.35M12.95M15.22M16.93M21.86M31.39M40.05M46.04M39.66M
Operating Income (Quarter)
-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.96M-19.86M-24.99M-16.09M-14.35M-12.95M-15.22M-16.93M-16.86M-18.89M-38.46M-44.13M-34.17M
EBIT (Quarter)
-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.96M-19.86M-24.99M-16.09M-14.35M-12.95M-15.22M-16.93M-16.86M-18.89M-38.46M-44.13M-34.17M
Non-operating items
Interest & Investment Income (Quarter)
-0.31M-0.72M-0.56M0.55M-0.01M0.01M2.19M-0.01M-0.06M2.74M-0.33M2.32M-0.09M2.20M0.01M2.64M2.27M
Other Non Operating Income (Quarter)
0.01M0.01M0.12M0.84M1.47M2.15M-0.05M-0.02M-0.10M0.27M-1.35M1.64M-0.01M0.01M-0.01M0.20M-0.01M-0.42M0.00M-0.01M
Non Operating Income (Quarter)
0.01M0.01M0.12M0.84M1.47M2.15M-0.05M0.23M0.98M1.12M-0.56M4.10M2.73M2.57M2.31M2.44M2.19M2.57M2.65M2.26M
Net income details
EBT (Quarter)
-54.99M-20.94M-27.58M-636.45M-34.23M-28.35M-17.43M-49.79M-53.23M-18.18M-16.14M-10.25M-10.21M-12.65M-15.91M-14.41M-16.70M-35.89M-42.21M-31.91M
Tax Provisions (Quarter)
0.00M0.50M0.00M0.00M
Profit After Tax (Quarter)
-14.59M-18.93M-25.84M-25.94M-25.25M-24.05M-12.67M-14.73M-18.88M-23.69M-16.65M-10.25M-9.63M-13.17M-14.62M-14.91M-16.51M-35.85M-41.49M-32.10M
Income from Continuing Operations (Quarter)
-54.99M-20.94M-27.58M-636.45M-34.23M-28.35M-17.43M-49.79M-53.23M-18.18M-16.14M-10.25M-10.21M-12.65M-15.91M-14.91M-16.70M-35.90M-42.21M-31.92M
Consolidated Net Income (Quarter)
-54.99M-20.94M-27.58M-636.45M-34.23M-28.35M-17.43M-49.79M-53.23M-18.18M-16.14M-10.25M-10.21M-12.65M-15.91M-14.91M-16.70M-35.90M-42.21M-31.92M
Income towards Parent Company (Quarter)
-54.99M-20.94M-27.58M-636.45M-34.23M-28.35M-17.43M-49.79M-53.23M-18.18M-16.14M-10.25M-10.21M-12.65M-15.91M-14.91M-16.70M-35.90M-42.21M-31.92M
Net Income towards Common Stockholders (Quarter)
-54.99M-20.94M-27.58M-636.45M-34.23M-28.35M-17.43M-49.79M-53.23M-18.18M-16.14M-10.25M-10.21M-12.65M-15.91M-14.91M-16.70M-35.90M-42.21M-31.92M
Additional items
EPS (Basic) (Quarter)
-7.29-5.07-3.58-81.63-4.34-3.62-2.18-6.14-6.51-2.23-3.42-0.40-0.38-0.59-0.58-0.53-0.59-1.25-1.35-1.02
EPS (Diluted) (Quarter)
-7.29-5.07-3.58-81.63-4.34-3.62-2.18-6.14-6.51-2.23-3.42-0.40-0.38-0.59-0.58-0.53-0.59-1.25-1.35-1.02
Shares Outstanding (Quarter)
7.54M4.13M7.72M7.80M7.89M7.84M7.98M8.11M8.18M8.15M4.72M25.61M27.17M21.28M27.53M28.08M28.54M28.81M31.35M31.37M
Shares Outstanding (Diluted) (Quarter)
7.54M4.13M7.72M7.80M7.89M7.84M7.98M8.11M8.18M8.15M4.72M25.61M27.17M21.28M27.53M28.08M28.54M28.81M31.35M31.37M
Shares Outstanding (Entity) (Quarter)
8.30M4.13M8.29M8.32M8.31M8.32M8.31M8.28M8.28M8.15M4.72M25.87M27.50M21.28M27.54M28.50M28.59M31.34M31.35M31.42M
EBITDA (Quarter)
-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.96M-19.86M-24.99M-16.09M-14.35M-12.95M-15.22M-16.93M-16.86M-18.89M-38.46M-44.13M-34.17M
Interest Expenses (Quarter)
40.39M2.00M1.32M608.95M7.52M2.14M4.82M34.81M33.38M-4.62M0.04M1.68M1.60M1.79M1.30M1.15M1.03M0.03M0.72M0.64M
Tax Rate (Quarter)
-0.01%-3.47%-0.01%-0.01%